ArticleWiener klinische Wochenschrift2012
[Diabetes Care Austria 2009: registry for type 2 diabetic patients in general practitioners' ordinations in Austria].
Article in Wiener klinische Wochenschrift, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
- Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.Wiener klinische Wochenschrift · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes Care Austria was a nationwide data acquisition of type 2 diabetes treatment at Austrian general practitioners. A total of 5,385 general practitioners were contacted in the end of 2009; finally, 101 agreed to participate in the data collection. Out of all 9 Austrian provinces, a cross-sectional sample of 1.513 type 2 diabetic patients was investigated. Demographic data, diabetes treatment, quality of diabetes control as well as micro- and macrovascular complications were analysed with respect to diabetes duration, categorised into 6 classes. A total of 1.513 type 2 diabetic patients with a mean age of 65.4 ± 10.7 years and a mean diabetes duration of 8.7 ± 7.3 years were analysed. Metformin was equally used in more than 50% of patients in all classes of diabetes duration. The use of sulfonylureas was significantly (p < 0.001) increased from 25% in patients with a diabetes duration of less than 3 years to more than 40% in subjects with a disease duration of longer than 15 years. The prescription of glitazones was significantly (p = 0.02) augmented with increasing diabetes duration. DPP-4 inhibitors were used in more than 5% of patients with a maximum of 13% in subjects with a diabetes duration of 4-9 years (p < 0.001). The mean HbA1c was below 7.5% in all classes and was significantly (p < 0.01) the lowest with 7.0 ± 1.2% in patients with the shortest diabetes duration when compared to all other categories. Diabetes Care Austria yielded representative data for diabetes therapy of type 2 diabetic patients treated by general practitioners. Diabetes treatment was successful, as proven by a mean HbA1c value of 7.2%. An insulin therapy was initialised late, but was nevertheless effective as shown by comparable HbA1c values in patients with a diabetes duration of 4 to more than 15 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.